Latest publications

IgE levels in patients with atopic dermatitis steadily decrease during treatment with dupilumab regardless of dose interval. Dekkers C, Van der Wal MM, Van den Noort L, Bakker DS, De Bruin-Weller M, Van Wijk F et al. Clin Exp Allergy 2023 Sep 12

Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps. Van der Rijst LP, Van Royen-Kerkhof A, Pasmans SGMA, Schappin R, De Bruin-Weller MS, De Graaf M et al. J Dermatolog Treat 2023 Dec; 34(1):2254567

Prognostic Factors for Long-term Aesthetic Outcome of Infantile Haemangioma Treated with Beta-blockers. Hermans MM, Pasmans SGMA, De Graaf M, Ragamin A, Mendels EJ, Breur JMPJ et al. Acta Derm Venereol 2023 Aug 30; 103:adv5286

Age and fast initial response predict omalizumab retreatment in chronic urticaria. Meertens MAJ, Luijf T, Van Lindonk EAM, Soegiharto R, Assil S, Alizadeh Aghdam M et al. J Allergy Clin Immunol Pract 2023 Jul 28

Correction to: Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma. Hermans MM, Rietman AB, Schappin R, De Laat PCJ, Mendels EJ, Breur JMPJ et al. Eur J Pediatr 2023 Jun 26

Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. Reich K, Silverberg JI, Papp KA, Deleuran M, Katoh N, Strober B et al. J Eur Acad Dermatol Venereol 2023 Jun 19

A European-Japanese study on peach allergy: IgE to Pru p 7 associates with severity. Kallen EJJ, Revers A, Fernández-Rivas M, Asero R, Ballmer-Weber B, Barreales L et al. Allergy 2023 Sep; 78(9):2497-2509

Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16. Thyssen JP, De Bruin-Weller M, Costanzo A, Grond S, Schuster C, Liu C et al. Adv Ther 2023 Aug; 40(8):3574-3587

Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. Reich K, Silverberg JI, Papp KA, Deleuran M, Katoh N, Strober B et al. J Eur Acad Dermatol Venereol 2023 Jun 15

Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics. Thyssen JP, Thaçi D, Bieber T, Gooderham M, De Bruin-Weller M, Soong W et al. J Eur Acad Dermatol Venereol 2023 Sep; 37(9):1871-1880

Component Ana o 3 versus extract for cashew nut allergy: A diagnostic test accuracy study in adults. Kallen EJJ, Bollemeijer JF, Knulst AC, Ehlers AM, Welsing PMJ, Van Ree R et al. Clin Exp Allergy 2023 Aug; 53(8):880-882

Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial. Simpson EL, Silverberg JI, Thyssen JP, Viguier M, Thaçi D, De Bruin-Weller M et al. Am J Clin Dermatol 2023 Jul; 24(4):609-621

Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials. Stein Gold L, Thaçi D, Thyssen JP, Gooderham M, Laquer V, Moore A et al. Am J Clin Dermatol 2023 Jul; 24(4):595-607

Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry. Spekhorst LS, Boesjes CM, Loman L, Zuithoff NPA, Bakker DS, Kamphuis E et al. Br J Dermatol 2023 Aug 24; 189(3):327-335

Limited excretion of dupilumab into breastmilk: A case report. Dekkers C, El Amrani M, Van Luin M, Bakker D, Plusjé L, Van Wijk F et al. J Eur Acad Dermatol Venereol 2023 Sep; 37(9):e1154-e1155